Cell Talk Technology Transfers for CGT products: Understanding what is needed for success Transferring a cell and gene therapy (CGT) product from development to manufacturing involves a detailed…Cell TherapiesJune 20, 2024
Cell Talk Quality Assurance: The Importance of Robust Investigations Quality Assurance: The Importance of Robust Investigations Quality Assurance (QA) is a broad process that…Cell TherapiesApril 22, 2024
Cell Talk Ensuring Every Batch is a Success: Validation and Qualification Ensuring Every Batch is a Success: Validation and Qualification in Cell and Gene Therapy Manufacturing…Cell TherapiesMarch 10, 2024
Cell Talk Translating research discoveries to commercialised cell and gene therapy products; asking the right questions as an academic. When translating research discoveries in the cell and gene therapy sector, numerous considerations must be…Cell TherapiesNovember 28, 2023
Cell Talk From Concept to Commercialisation: Why the selection of an organisation for a cell and gene therapies can impact your patient outcomes and competitive advantage The development pipeline of cell and gene therapies faces numerous obstacles while striving for the…Cell TherapiesAugust 14, 2023
Cell Talk Translating innovative cell therapies: What is GMP? The cell therapy sector is growing rapidly and within it, cell-based therapies derived from human…Cell TherapiesMay 22, 2023
News Cell Therapies to partner with Chimeric Therapeutics Ltd Cell Therapies are pleased to announce that they are partnering with Chimeric Therapeutics to…Josh DowningAugust 9, 2024
News CTPL to be AdAlta’s preferred manufacturer of immunotherapies Cell Therapies Pty Ltd to be preferred manufacturer of cellular immunotherapies Establishes key partnership to…Cell TherapiesMay 12, 2024
News Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing…Cell TherapiesNovember 8, 2023